GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » 10-Year ROIIC %

SciClone Pharmaceuticals (SciClone Pharmaceuticals) 10-Year ROIIC % : 0.00% (As of Dec. 2016)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. SciClone Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2016 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for SciClone Pharmaceuticals's 10-Year ROIIC % or its related term are showing as below:

SCLN's 10-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.16
* Ranked among companies with meaningful 10-Year ROIIC % only.

SciClone Pharmaceuticals 10-Year ROIIC % Historical Data

The historical data trend for SciClone Pharmaceuticals's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals 10-Year ROIIC % Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SciClone Pharmaceuticals's 10-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals's 10-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals's 10-Year ROIIC % falls into.



SciClone Pharmaceuticals 10-Year ROIIC % Calculation

SciClone Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2016 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( 29.9214705 (Dec. 2016) - -8.924 (Dec. 2006) )/( 82.747 (Dec. 2016) - 12.87 (Dec. 2006) )
=38.8454705/69.877
=55.59%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


SciClone Pharmaceuticals  (NAS:SCLN) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


SciClone Pharmaceuticals 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480